title: IK-guided PP2A suppresses Aurora B activity in the interphase of tumor cells.
abstract: Aurora B activation is triggered at the mitotic entry and required for proper microtubule-kinetochore attachment at mitotic phase. Therefore, Aurora B should be in inactive form in interphase to prevent aberrant cell cycle progression. However, it is unclear how the inactivation of Aurora B is sustained during interphase. In this study, we find that IK depletion-induced mitotic arrest leads to G2 arrest by Aurora B inhibition, indicating that IK depletion enhances Aurora B activation before mitotic entry. IK binds to Aurora B, and colocalizes on the nuclear foci during interphase. Our data further show that IK inhibits Aurora B activation through recruiting PP2A into IK and Aurora B complex. It is thus believed that IK, as a scaffold protein, guides PP2A into Aurora B to suppress its activity in interphase until mitotic entry.
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Sunyi
authors.initials: S
authors.lastname: Lee
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Ae Lee
authors.initials: AL
authors.lastname: Jeong
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Jeong Su
authors.initials: JS
authors.lastname: Park
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Sora
authors.initials: S
authors.lastname: Han
authors.affiliation: Research Center for Cell Fate Control, College of Pharmacy, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Chang-Young
authors.initials: CY
authors.lastname: Jang
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Keun Il
authors.initials: KI
authors.lastname: Kim
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Yonghwan
authors.initials: Y
authors.lastname: Kim
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Jong Hoon
authors.initials: JH
authors.lastname: Park
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Jong-Seok
authors.initials: JS
authors.lastname: Lim
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea.
authors.forename: Myung Sok
authors.initials: MS
authors.lastname: Lee
authors.affiliation: Division of Biological Sciences, Department of Life Systems, Research Center for Women's Disease, Sookmyung Women's University, Seoul, 140-742, Republic of Korea. yyang@sm.ac.kr.
authors.forename: Young
authors.initials: Y
authors.lastname: Yang
mesh_terms: D064107:Aurora Kinase B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects; D057809:HEK293 Cells; D006367:HeLa Cells; D006801:Humans; D007399:Interphase; D059566:M Phase Cell Cycle Checkpoints; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D054648:Protein Phosphatase 2 / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000302:isolation & purification; D014404:Tubulin / Q000378:metabolism
chemical_list: C474722:4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline; D001549:Benzamides; D016207:Cytokines; C090444:IK protein, human; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D034741:RNA, Small Interfering; D011994:Recombinant Proteins; D014404:Tubulin; C576921:AURKB protein, human; D064107:Aurora Kinase B; D054648:Protein Phosphatase 2
keywords: Aurora B; Cell cycle; IK; Interphase; Mitosis; PP2A; Protein RED